Cargando…
PSA Response to Lenalidomide Therapy in a Pre-Treated Patient with Metastatic Prostate Cancer Refractory to Hormones and Chemotherapy: A Case Report
Hormone-resistant prostate cancer (HRPC) occurs when prostate cancer is no longer responsive to hormone therapy. Treatment options are limited, and there is a clear necessity for therapies that improve outcome. Preclinical and clinical evidence supports the role of the immunomodulatory agent lenalid...
Autores principales: | Gasent Blesa, Joan Manel, Godoy, Miguel Peris, Esparcia, María Fonfría, Mollá, Sara Blasco, Magán, Balbino Mancheño, Sempere Ortells, José Miguel, Sánchez, José Luis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364036/ https://www.ncbi.nlm.nih.gov/pubmed/22666210 http://dx.doi.org/10.1159/000336481 |
Ejemplares similares
-
Durable Complete Remission of a Brainstem Glioma Treated with a Combination of Bevacizumab and Cetuximab
por: Blesa, Joan Manel Gasent, et al.
Publicado: (2012) -
PSA Decrease with Fulvestrant Acetate in a Hormone-Resistant Metastatic Prostate Cancer Patient: A Case Report
por: Gasent Blesa, Joan Manel, et al.
Publicado: (2009) -
Carcinomatous Pericarditis in 3 Breast Cancer Patients with Long-Term Survival
por: Konishi, Takanori, et al.
Publicado: (2012) -
Incidental MRI Findings of Acute Gadolinium Hypersensitivity
por: Amene, C., et al.
Publicado: (2012) -
Ectopic Sebaceous Glands in the Esophagus: Endoscopic Findings over Three Years
por: Fukuchi, Minoru, et al.
Publicado: (2012)